13 May 2020

Catabasis Pharmaceuticals has presented important information updates on the Edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session.

The information updates presented outline the potential for Edasalonexent to provide positive effects for DMD including:

  • Capsule swallowing abilities
  • Expected patient population
  • Growth patterns and adrenal function

Edasalonexent is being developed as a potential foundational therapy aimed at improving the lives of all patients affected by DMD, regardless of their underlying mutation.

To learn more visit: https://www.catabasis.com/Catabasis%20Newsletter%20May%202020%20.pdf

To read more about Edasalonexent visit: https://www.catabasis.com/our-science/edasalonexent.php